title: Incorporating quality of life data into managed care formulary decisions: a case study with salmeterol.
abstract: Pharmacy and Therapeutics committees of managed care organizations have traditionally developed formularies by limiting the numbers and kinds of pharmaceuticals they purchase, with the goal of cutting costs. These attempts to manage pharmaceutical costs do not take into account the interrelationship of the costs of various components of care; thus, drug costs may decrease, but expenditures for utilization of other resources may increase. Cost-minimization and basic cost-effectiveness studies, on which many prior- authorization and formulary programs are based, only evaluate only the cost of the drug and its effectiveness. However, with the heightened competition in the healthcare market, emphasis is increasingly being laid on patient satisfaction and outcomes. Cost-utility analysis is a potentially superior pharmacoeconomic tool because it evaluate the effect of drug therapy on quality of life; however, data from such analyses are seldom readily available to the committees that evaluate a drug's potential effects on the entire healthcare system. The purpose of this review is to stress the importance of approaching formulary management from a wider perspective and to emphasize that the results of cost-utility studies should be proactively evaluated and incorporated into decisions regarding formularies. This is especially important for symptom-intensive diseases, such as asthma, in which the quality of life can be notably impaired. Cost-utility analyses should be conducted for all newer therapies, such as salmeterol, which are highly effective and which have a positive impact on quality of life, to determine the overall effect on the managed care plan's budget.
authors.affiliation: Dean Medical Center, Madison, WI 53715, USA.
authors.forename: D A
authors.initials: DA
authors.lastname: Bukstein
mesh_terms: D000420:Albuterol / Q000031:analogs & derivatives* / Q000191:economics / Q000627:therapeutic use; D018927:Anti-Asthmatic Agents / Q000191:economics* / Q000627:therapeutic use; D001249:Asthma / Q000188:drug therapy; D003362:Cost-Benefit Analysis; D003659:Decision Making, Organizational; D005569:Formularies as Topic; D006801:Humans; D008329:Managed Care Programs / Q000458:organization & administration*; D019982:Organizational Case Studies; D017063:Outcome Assessment, Health Care; D017060:Patient Satisfaction; D010606:Pharmacy and Therapeutics Committee; D011788:Quality of Life; D000068299:Salmeterol Xinafoate; D014481:United States